Genetic errors that cause creatine deficiency don’t stop the transporter from being made, but they break it in specific ways—like jamming the ion channels, warping the shape, or loosening the structure—so it can’t move creatine into cells.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Definitive classification of all known SLC6A8 mutations by functional and structural impact.
A systematic review of all published SLC6A8 variants, integrating structural data, functional assays, and clinical phenotypes to create a comprehensive mutation impact database.
Causal effect of gene therapy or chaperone drugs on CCDS1 outcomes.
A double-blind RCT of 60 male CCDS1 patients randomized to gene therapy vs placebo, measuring cognitive development, brain creatine (MRS), and safety over 24 months.
Natural history of CCDS1 and genotype-phenotype correlations.
A prospective cohort of 150 CCDS1 patients followed from diagnosis, tracking developmental milestones, seizures, and correlating with mutation class (e.g., folding vs binding).
Association between mutation location and brain creatine levels.
A cross-sectional MRS study of 70 CCDS1 patients, comparing brain creatine concentration between those with binding-site vs. folding mutations.
Hypothetical models of mutation impact based on clinical experience.
A review article summarizing clinical features of CCDS1 and proposing functional consequences of mutations.